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ABSTRACT
PRECLINICAL DEVELOPMENT OF EPICERTIN, A NOVEL BIOTHERAPEUTIC
FOR THE TREATMENT OF ULCERATIVE COLITIS
Micaela Ann Reeves
April 6, 2021
Epicertin (EPT) is a recombinant variant of the cholera toxin B subunit with a Cterminal KDEL endoplasmic retention motif. Previously, orally administered EPT
demonstrated mucosal healing activity in acute and chronic dextran sulfate sodium colitis
models, indicating its therapeutic potential for ulcerative colitis (UC) treatment.
However, oral dosing with EPT requires neutralization of gastric acid prior to
administration, hindering its facile application in the treatment of chronic diseases like
UC. One solution to this issue is that EPT may also be administered intracolonically
without losing efficacy. This work describes the determination of a target intracolonic
dose of EPT for future first-in-human safety trials as well as the development of a
prototype oral formulation of EPT that prevents stomach acid degradation for pHdependent release at the colon.
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CHAPTER 1: INTRODUCTION

The cholera toxin B subunit (CTB) is the homopentameric subunit of the cholera
toxin. The cholera toxin is comprised of this nontoxic B subunit and the toxic catalytic A
subunit [1-3]. CTB binds to GM1 ganglioside to mediate entry of the whole toxin into the
cell via retrograde transport to the endoplasmic reticulum (ER) [4]. CTB exhibits strong
immunomodulatory effects under normal and various immunopathological conditions [5,
6]. For example, a WHO pre-qualified oral cholera vaccine, Dukoral®, contains heatkilled whole cell Vibrio cholerae and recombinant CTB [5, 7]. However, CTB can induce
potent mucosal and systemic antibody responses in humans on its own [8-10]. A plantmade recombinant CTB variant, epicertin (EPT), featuring a C-terminal hexapeptide ER
retention motif -KDEL exhibits mucosal healing activity unlike CTB. A unique feature of
EPT is its established ability to be efficiently manufactured in a Nicotiana benthamiana
transient production system [11]. EPT was initially engineered as a potential solution to
the cost and scale challenges in CTB biomanufacturing to aid in mass vaccination against
cholera outbreaks [12, 13]. However, EPT may have a separate role as a potential novel
therapeutic for ulcerative colitis [14].
Ulcerative colitis (UC) is a major form of inflammatory bowel disease (IBD),
characterized by chronic and relapsing inflammation of the innermost layer of the colon
and rectal mucosa [15, 16]. Its etiology remains poorly understood and the onset is
associated with a complicated interplay of genetic and environmental factors as well as gut
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microbiota [17]. The disease often manifests as a multitude of symptoms: bloody diarrhea,
rectal bleeding, fatigue, and weight loss. However, symptom presentation often varies
among patients and may change over time with increasing severity of disease [16]. The
Crohn’s and Colitis Foundation estimates that approximately 1.6 million Americans suffer
from IBD with a total US annual financial burden between $14.6 billion and $31.6 billion.
UC accounts for 907,000 of these cases with an annual incidence of 12.2 per 100,000
people [16]. Current FDA-approved UC drugs aim to treat existing symptoms, maintain
remission, and improve quality of life. Despite multiple treatment options available to UC
patients, none of them can cure the disease, and up to a third of those with 30+ years of the
disease will require surgical removal of the colon and rectum [16].
There are several classes of drugs used to treat UC [16]. Typically, UC treatment
follows a step-up approach in which drug class utilization is dependent upon disease
severity and response to prior therapies. The final step of this treatment strategy is
surgical intervention [18, 19]. Treatment with 5-aminosalicylates (ASAs) has long been
the mainstay first-line therapy for mild-to-moderate UC [16, 20]. This inflammationblunting class of therapeutics are preferred for early-stage UC because of their generally
innocuous side effect profiles, although moderate UC is often unresponsive to these
agents [19]. The mild side effect profile is counteracted by the ability of patients to
develop tolerance during remission maintenance and require new treatment strategies.
Failure to achieve or maintain remission with 5-ASAs is typically followed by treatment
with corticosteroids and steroid-sparing immunomodulators. An estimated two-thirds of
patients receiving short-term steroid treatment for moderate to severe UC achieve
remission. However, the risk of serious adverse effects limit long-term use of these
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agents [18-21]. Biologics (e.g. anti-TNFα and anti-integrin monoclonal antibodies) have
traditionally been the final agents utilized to treat severe UC prior to surgical resection of
the colon and rectum, although recent literature suggests the benefit of using biologics in
earlier stages [22]. These drugs are effective in remission induction and maintenance in
patients following previous treatment failures but are partnered with the serious side
effects including severe infection and increased cancer risk [20, 21]. Of particular note,
fewer than half of patients treated with biologics are able to achieve mucosal healing, an
endoscopic marker found to be highly predictive of sustained clinical remission, better
quality of life, and decreased risk for colitis-associated colorectal cancer [23, 24].
Further, biologics are typically more expensive than other therapeutic agents [25].
Therefore, there is a current unmet need in UC therapy: agents that can directly restore
the damaged epithelial barrier and facilitate mucosal healing without suppressing immune
function such as EPT. In this chapter, I will summarize previous studies describing the
mucosal healing activity of EPT, discuss the current EPT formulations under
investigation and limitations as well as describe other potential formulation options.

1.1. EPT facilitates mucosal healing: A novel therapeutic target for ulcerative colitis.

Although originally designed to aid mass vaccination efforts against cholera
outbreaks, we also assessed the immunomodulatory effects of EPT. Two weeks after two
oral 30 µg administrations of EPT, immune cell population analysis from the small
intestine, colon, Peyer’s patches, and spleen revealed that subsets of innate immune cell
populations in the lamina propria of the colon were significantly increased in EPT-treated
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mice compared to control (M1 and M2 macrophages confirmed by
immunohistochemistry, natural killer [NK] cells). T helper (Th)2, regulatory T (Treg) and
Th17 cells were also increased following administration of EPT. Gene expression
analysis further supported that EPT has a more targeted impact on the colon as 871 genes
were significantly altered in the colon (p < 0.01) while 184 genes were significantly
altered in the small intestine in mice treated with EPT compared to vehicle control. Oral
administration of EPT was shown to induce TgfbI, TgfbII receptor and Smad regulation,
all of which are genes involved in transforming growth factor (TGF)β-associated
pathways and epithelial wound healing [26]. For this reason, epithelial restitution
potential of EPT was assessed using a human colon epithelial cell (Caco2) scratch assay.
EPT significantly enhanced epithelial cell migration similarly to the TGFβ1 control
compared to the vehicle control phosphate buffered saline (PBS) at 24 and 48 h post
scraping the cell layer. Cell culture supernatant analyzed at 48 h showed that epicertin
and TGFβ1 had similar inflammation and wound healing-related profiles relative to
cytokines like epidermal growth factor (EGF), granulocyte colony-stimulating factor (GCSF), granulocyte-macrophage (GM)-CSF, interferon (IFN)-γ, interleukin (IL)-10, IL-6,
and tumor necrosis factor (TNF)α. This effect translated to an in vivo model of acute
colitis induced by dextran sulfate sodium (DSS). EPT treatment significantly blunted
weight loss induced by DSS and hematoxylin and eosin (H&E)-stained distal colon tissue
at 6 days post-DSS exposure reveled that EPT administration prevented crypt loss and
ulceration compared to vehicle control. However, the numbers of infiltrating
macrophages into the colon mucosa were similar between EPT and vehicle groups.
Another in vivo study was performed to assess the immediate impact of EPT treatment on
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acute DSS-induced colitis. Mice were orally administered 30 µg EPT or PBS twice
before DSS exposure. A reference group of mice dosed daily with 100 µg mesalazine
during DSS exposure was also included. EPT- and mesalazine-treated mice similarly
reduced mucosal damage as characterized by shorted yet visible basal crypts, mild
inflammatory infiltrates, and epithelial cell surface retention. Gene expression and
cytokine analysis from the distal colon showed that EPT treatment blunted escalation of
inflammatory markers including IL-1β, IL-6, and IFN-γ among others. In an
azoxymethane (AOM)/DSS mouse model of chronic colitis and colon cancer, biweekly
EPT administration (3 µg) significantly decreased disease activity index (DAI) scores
following the first dose and more dramatically during the third DSS exposure period.
This is a standard scoring system assessing the overall severity of colitis, which takes an
average of scores from three categories: body weight, stool consistency, and blood in
stool [27]. Tumorigenesis was also significantly reduced in both dose groups treated with
EPT [14]. Taken together, these results highlight the potential role of EPT in UC therapy
as a mucosal healing agent that specifically targets the colon.

Mucosal healing is a major treatment goal for UC patients [23, 24, 28, 29]. It is a
complex and dynamic process involving multiple cell types including epithelial, stromal,
and immune cells [28]. Epithelial repair plays a crucial role in mucosal healing by
rebuilding the intestinal barrier to inhibit inflammation caused by entry of bacteria into
the mucosa. Since inflammation in UC is limited to the innermost layer of the colon and
rectal mucosa, epithelial repair may be key to effectively achieving mucosal healing in
this subset of IBD patients [16, 23]. Currently there is no UC drug approved by FDA that
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specifically aims at recovering the colon epithelial barrier integrity. Thus, an epithelial
repair agent, such as EPT, may fill a current treatment gap for UC.

We continued to investigate the mechanism of EPT-induced mucosal healing via
epithelial repair, specifically the importance of its ER retention motif [30]. To test the ER
retention activity of EPT, Caco2 cells were treated with EPT or CTB for 24 h and cell
lysates were monitored for CTB retention for 24 h. While CTB showed decreasing levels
of retention with only marginal amounts detected at 24 h, EPT was continuously detected
in cell lysates over 24 h. These results were corroborated with confocal microscopy in
which EPT was depicted at much higher amounts inside Caco2 cells at 6 and 24 h
compared to CTB. Coimmunoprecipitation results also indicated that EPT displayed clear
binding to KDEL receptors that was not observed with CTB. These data indicate that
EPT has prolonged residence in Caco2 cells due to its KDEL receptor interaction.

In Caco2 cells treated with EPT, CTB, a non-GM1 binding mutant of EPT (G33D
EPT) or PBS, it was demonstrated that all 3 sensors of the unfolded protein response
(UPR) pathways were upregulated at gene expression and protein levels only in EPTtreated cells [30]. The UPR is a system in which the ER can activate various intracellular
signaling pathways to alleviate the accumulation of aberrant proteins. However, this
response can also be triggered by adventitious proteins invading the ER, such as CTB
[31, 32]. One branch of the UPR, the inositol-requiring enzyme 1 (IRE1)- X-box binding
protein 1 (XBP1) pathway has been linked to wound healing and mitigation of DSS
colitis [33-35]. Some of the markers of the UPR analyzed were activating transcription
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factor 6 (ATF6), PKR-like ER kinase (PERK), IRE1, and immunoglobulin heavy chainbinding protein (BiP). Consistent with the Caco2 study, mouse primary colon epithelial
cells treated with EPT for 24 h also significantly increased levels of IRE1α, PERK, and
BiP compared to CTB and PBS-treated groups. A further coimmunoprecipitation assay
indicated that Caco2 cells incubated with CTB or EPT for 1 h both were shown to
interact with the ER chaperone, BiP, however, only EPT was shown to interact with BiP
after 24 h. To test the impact of the UPR on EPT’s wound healing activity, a Caco2
scratch assay was performed in which cells were treated with EPT in the presence or
absence of 4µ8C, a chemical inhibitor of the IRE1-XBP1 arm of the UPR. The UPR
inhibitor was sufficient to completely block the wound closure activity of EPT, indicating
that EPT exhibits wound healing activity via the IRE1-XBP1 signaling pathway [30].

Since EPT was demonstrated to activate an UPR in primary mouse colon
epithelial cells, it was hypothesized that this enhanced epithelial repair was mediated by
the IRE1 arm of the UPR. Most interestingly, these findings were also evaluated in
human colon tissues ex vivo [30]. A sigmoid colon tissue of a UC patient who underwent
total colectomy was sectioned into 9 pieces and cultures with EPT, CTB, or PBS (n=3)
for 24 h. Following incubation, UPR, TGF-β, and wound healing gene expression was
analyzed. Consistent with Caco2 cell results, EPT-treated tissue showed a significant
upregulation in the IRE1 gene (ERN1), PERK gene (EIF2AK3), and TGF-B1 with no
significant difference observed between PBS- and CTB-treated tissues. Histopathological
analysis showed the EPT-treated tissues also had early-stage crypt formations with low
mucosal neutrophil infiltration, both of which were not seen in the PBS- or CTB-treated
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tissues. Altogether, the results of this study indicate that EPT has unique colon mucosal
wound healing effects related to its ER retention and subsequent activation of the UPR
[30].

In another study we evaluated the efficacy of EPT in the treatment of chronic
colitis as well as addressed consequences of immunogenicity [36]. A chronic DSS colitis
experiment in which mice were exposed to three cycles of 7-day DSS in drinking water
followed by 14-day normal drinking water was performed (total in-life study period of 63
days). Mice were treated orally with 3 µg EPT or PBS once weekly starting on day 7,
with 3 µg EPT or PBS once weekly starting on day 35, or with 3 µg EPT or PBS every 3
days starting at day 35 (6 dosing groups total). All EPT-treated groups showed immediate
reduction in DAI scores. Mice receiving weekly EPT treatment starting from day 7 and
every-3-day treatment from day 35 appeared to have improved barrier function compared
to PBS-treated groups as indicated by serum FITC-dextran measurements at the
conclusion of the study on day 63. No EPT treatment groups demonstrated an elevation
of analyzed pro-inflammatory cytokines (IL-1β, TNFα, GM-CSF, and IFN-γ). Once
weekly treatment with EPT starting at day 7 significantly decreased GM-CSF and IL-1β
levels compared to PBS, and once weekly treatment with EPT starting at day 35
significantly decreased GM-CSF and IFNγ levels compared to PBS. Histopathological
examination corroborated the DAI, FITC-dextran, and cytokine analyses. Mice dosed
with EPT once weekly starting from day 7 or every-3-day starting from day 35
demonstrated similar recovery and exhibited less crypt branching, crypt distortion, and
expansion of the lamina propria than weekly dosing starting at day 35. These results
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taken together indicate that once weekly or every-3-day EPT dosing can effectively
mitigate chronic colitis and that the efficacy is maintained over a long period, raising an
interesting question about the consequences of an immune response to the protein, which
is derived from the mucosal immunostimulatory protein CTB.

To probe the potential impacts of anti-drug antibodies, an acute DSS study was
performed in which three groups of C57Bl/6 mice were administered either two oral
doses of 30 µg EPT prior to DSS exposure, dosed only one therapeutic dose of 3 µg EPT
on the final day of 7-day DSS exposure, or received both two oral doses of 30 µg EPT
prior to DSS exposure and one therapeutic dose of 3 µg EPT on the final day of DSS
exposure. Anti-EPT IgA titers were assessed on days 7 and 14 to determine if the
immunogenicity of EPT impacts its efficacy. All EPT-treated groups showed a
significantly more rapid body weight recovery after DSS cessation and all EPT groups
showed similar DAI scores that were significantly lower than the PBS-treated mice. Both
groups in which mice were dosed prior to DSS exposure had similar and high levels of
anti-EPT IgA antibodies at days 7 and 14, indicating that anti-drug antibodies were
present when EPT was administered therapeutically. Under the same experimental
condition in C3H/HeJ mice, which are poor responders to CTB immunization, all EPT
epicertin dose regimens were efficacious against DSS colitis compared to PBS-treated
mice in terms of body weight recovery, colon length and DAI scores. Unlike the
C57BL/6 mice, however, these mice had little or no anti-CTB IgA response to pre-dosing
with EPT, indicating that EPT’s therapeutic effects are unlikely dependent on IgA
induction in the intestine. These results demonstrate that the immunogenicity of EPT
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dosing does not seem to impede its mucosal healing efficacy, further supporting the
potential role of this molecule as a novel therapeutic for UC [36].

1.2. Current production process and formulation of EPT

The EPT production process has continuously been optimized over the last several
years [11-13, 37]. This variant of CTB is transiently overexpressed in a species of tobacco,
Nicotiana benthamiana. Utilization of the GENEWARE® tobacco mosaic virus vector, we
are able to purify approximately 400 mg of EPT per kg of leaf tissue [37]. EPT is expressed
using the GENEWARE® tobacco mosaic virus vector and inoculated into 21-day old N.
benthamiana. Eleven days post-infection leaf tissues are harvested and EPT is extracted
using a commercial blender and a 1:2 ratio of leaf tissue to extraction buffer. Following
filtration and centrifugation steps, the supernatant is heated at 50°C for 45 min and
undergoes further centrifugation to precipitate starches and host proteins. The pH of the
resulting supernatant is adjusted from pH 5.0 to 8.0 to precipitate the one more round of
host proteins prior to purification. The EPT-containing supernatant is first purified by
immobilized metal affinity chromatography (IMAC) using a metal affinity resin charged
with CoCl2. This purification method utilizes CTB’s ability to bind to divalent metal
cations through internal histidine residues [38]. A second chromatography step using a
ceramic hydroxyapatite resin with a gradient phosphate buffer elution step is used to isolate
fully intact EPT from EPT species with truncations of the C-terminal -KDEL motif. By
this two-step chromatography method we are able to achieve approximately 95% purity of
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fully intact EPT [11]. The resulting drug product is a solution of EPT in PBS (pH 7.4) that
is stored at 4°C.
EPT may be administered to the colon topically or by oral gavage to alleviate DSSinduced colitis in mice [30]. Although oral medications are generally preferred by patients
and increase patient adherence to treatment regimens [17, 39, 40], oral administration of
EPT solution requires neutralization of stomach acid to prevent degradation of the protein.
This is similar to the WHO prequalified oral cholera vaccine, Dukoral®, which is
administered in a solution following stomach neutralization with a sodium bicarbonate
solution. Considering potential long-term treatment necessary for the management of UC
[41], this neutralization step could be disadvantageous as it would likely lower patient
adherence and ease of administration. Intracolonic administration is another option for
EPT, as many UC drugs are enemas. However, enema formulations have their own
advantages as well as limitations.

1.3. Routes of administration with respect to ulcerative colitis.

Deciding on a route of administration for a drug is not necessarily an easy choice
when presented with multiple formulation possibilities. For EPT, several factors must be
taken into consideration when deciding whether to move forward with an enema or oral
formulation. An enema formulation has the benefit of direct topical application to the
target site as well as lower potential for systemic off-target effects [17]. This would
decrease the number of safety concerns that would need to be addressed during
preclinical and clinical investigations. Intracolonic administration allows for rapid
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absorption of the drug and ensures delivery of optimal dosage as it by-passes first-pass
metabolism [17]. Enema formulations can be especially beneficial to treat UC affecting
the rectum and most distal sections of the colon [17]. However, enema formulations run
the risk of decreasing patient adherence and are not as easily administered, two important
factors to consider when developing drugs to treat chronic diseases like UC [41].
Oral medications are generally preferred by patients, which increases the
likelihood that patients will adhere to treatment regimens [17, 39, 40]. They are easier for
patients to self-administer and can be formulated with delivery systems to extend release,
prevent stomach acid degradation, and allow for release of capsule contents at a specific
pH [17, 40]. These benefits are countered with the need for higher doses to compensate
for drug loss after first-pass metabolism and potential absorption throughout the GI tract
prior to delivery at the target site [17]. Higher doses correspond to increased production
costs per dose and ultimately higher costs for the patient. Further, development and
production systems required to manufacture a drug with a specialized coating or delivery
system can slow research efforts and become costly. With respect to EPT, an enema
formulation is suitable for early safety and efficacy studies in humans, however, an
improved solid oral formulation allowing for release at the distal colon would be optimal
due to the need for adherence in the treatment of chronic diseases like UC.

1.4. Oral drug delivery options and dried formulations.

Biotherapeutics are often limited in their use as orally administered agents in UC
due to degradation in the gastrointestinal tract, large molecular size, and poor permeation
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[42]. Therefore, the formulation of the drug product must be optimized to circumvent
these issues. There are a variety of oral formulations currently used and more under
investigation for the manufacturing of biotherapeutics. The formulation strategy
employed depends on the properties of the drug itself. For example, poorly soluble drugs
can be delivered by reducing particle size or adding surfactants to the drug substance
[43]. Nanoparticle drug delivery systems are often used to protect a drug from the harsh
environment of the gastrointestinal tract [44]. Another drug delivery system commonly
used is an enteric polymer coating allowing for site-specific delivery based on pH. These
coatings are designed to remain stable and intact through the gastrointestinal tract and
degrade once exposed to a specific pH. This would be beneficial to prevent degradation
of EPT in the gastric acid. Other coatings are microflora-triggered and are biodegraded
by bacterial flora in the colon [43]. Drugs that utilize these coatings are often tablets or
capsules filled with lyophilized or spray-dried drug substances.

There are two main dehydration processes in the world of pharmaceutical and
biopharmaceutical development: spray drying and freeze drying (lyophilization) [45].
The primary drying method in industrial settings, lyophilization, is a two-step process in
which ice is sublimated from frozen drug product followed by desorption of remaining
water at low pressure and higher temperature to form a dried cake [46]. If a fine powder
is required, another process must be added to break up the final cake [47]. The addition of
this secondary step removes a certain amount of control from the manufacturers, reduces
efficiency and increases production time [47, 48]. Spray drying technology was originally
improved to aid formulation development of small molecule drugs but has gained
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popularity in the world of biopharmaceuticals in recent decades. In contrast to
lyophilization, spray drying is a one-step process in which the protein solution is
atomized into a hot air-drying chamber and resulting particles settle in a product collector
[48-50]. Although biopharmaceutical spray drying has its limitations on an industrial
scale, it offers the following advantages to lyophilization: consistent powder quality,
increased production control necessary to follow current Good Manufacturing Practice
(cGMP) guidelines, significant energy cost savings, a wide range of dryer designs for
specific applications, and ability to dry heat-sensitive and heat-resistant inputs [45]. For
this reason, in addition to continuing to evaluate safety and efficacy of an intracolonic
formulation of EPT, we began to develop an optimal oral formulation: a spray-dried
capsule with an enteric polymer coating allowing for pH-dependent release at the colon.
The results herein describe a dose analysis study to determine an optimal dose level for
intracolonically delivered EPT, as well as a prototype production process for a spraydried form of EPT and its efficacy as evaluated in an acute DSS colitis mouse model.
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CHAPTER II: MATERIALS AND METHODS

EPT production. EPT was produced in Nicotiana benthamiana using a transient
overexpression system and purified to > 95% homogeneity with an endotoxin level of <3
endotoxin

units

per

mg

as

described

previously

[11,

12,

37].

EPT

was

ultrafiltrated/diafiltrated into various buffers (Table 1) using 30,000 MWCO centrifugal
devices. PBS with 100 mM mannitol was found to be the optimal buffer for spray drying of
EPT. EPT at 1 mg/mL in PBS with 100 mM mannitol excipient (pH 7.2) was dehydrated
using a Büchi B-290 mini spray drier with an inlet temperature of 125°C and an outlet
temperature maintained between 65 and 67°C. The Q-Flow was 35 mm, aspirator was 90%
and pump 20%. EPT powder was stored in conical tubes wrapped in parafilm under
desiccation at room temperature (20-25ᵒC) until use. Standard EPT used for the GM1/KDEL
ELISA and SEC-HPLC was produced in Nicotiana benthamiana using a transient
overexpression system and purified to > 95% homogeneity with an endotoxin level of <3
endotoxin units per mg as described previously [11, 12, 37]

Acute DSS colitis model and EPT treatment for intracolonic dose level determination
study. Groups of 10 female C57BL/6 mice, randomly assigned, were used. 3% DSS (M.W.
36,000 – 50,000; M.P. Biomedicals, Santa Ana, CA) was administered in drinking water ad
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libitum for 7 days.1 Body weights were monitored daily from the start of DSS exposure to
sacrifice on day 12. On the last day of DSS exposure, animals were intracolonically
administered 100 µL of PBS, 0.01 µM EPT, 0.1 µM EPT, or 1 µM EPT (corresponding to
0.0614 mg, 0.614 mg, or 6.14 mg EPT per animal). Animals recovered with normal drinking
water for 5 days. Disease activity index (DAI) scores, consisting of body weight loss, fecal
consistency and occult blood tests, were recorded following sacrifice and performed as
previously described [51]. Distal colon tissues were fixed in neutral buffered formalin and
stained with hematoxalin and eosin (H&E). Histopathological scores, a combination score
comprised of crypt architecture, inflammatory infiltrate, muscle thickening and goblet cell
presences scores, were determined as previously described [52, 53]. Each category was
ranked on a scale from 0 to 3 and summed to obtain a single histopathological damage score
for each tissue.

EPT powder characterization. To measure residual moisture, a 5.9 mg portion of dried
powder was incubated at 70oC for 16 h. Moisture content was calculated by weighing the
difference before and after heating. To determine solubility, dried powder was weighed and
a calculated volume of milli Q water was added to reconstitute EPT powder to 1 mg/ml. The
concentration of the reconstituted solution was measured by Nanodrop (Thermo Fisher
Scientific) using an extinction coefficient at A280 of 0.7857. The percent solubility was
calculated based on the difference in 1 mg/mL vs the determined nanodrop concentration.

Eight-week-old C57BL/6J, female mice were obtained from Jackson Laboratories (Bar
Harbor, ME). The University of Louisville’s Institutional Animal Care and Use Committee
approved all animal studies conducted in this thesis.
1
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Percent monomer was determined by size-exclusion high performance liquid
chromatography (SEC-HPLC). SEC-HPLC was run as previously described [17]. Briefly,
reconstituted EPT at 1 mg/mL was applied to a Tosoh TSKgel SuperSW3000 column using
100 mM sodium phosphate, pH 7.2, 150 mM sodium chloride running buffer. EPT standard
(a bulk solution prepared in PBS before spray drying) was used as a control.

GM1-capture KDEL-detection (GM1/KDEL)-ELISA. The assay was done as described
in Morris et al. [11]. Plates were coated with 100 µL per well of 2 µg/mL GM1 ganglioside
(Sigma Aldrich; St. Louis, MO) diluted in a coating solution consisting of 3 mM sodium
azide, 15 mM sodium carbonate, 35 mM sodium bicarbonate, pH 9.6. After overnight
incubation (16 to 18 h) at 4ᵒC, plates were washed three times with PBST (0.05% Tween 20
in 1X PBS) and blocked with a blocking solution (5% non-fat dry milk, 0.05% Tween 20 in
1X PBS) for 1 h at room temperature, then washed with PBST thrice. Three-fold serially
diluted, duplicate samples (100 µL/well) were added to plates in 1% PBSTM (1% dry milk,
0.05% Tween 20 in 1X PBS). Samples were incubated on plates for 1 h at 37ᵒC. Plates were
washed and mouse anti-KDEL monoclonal antibody (Enzo Life Sciences; Farmingdale, NY)
diluted 1:1,000 in 1% PBSTM (100 µL/well) was added; plates were then incubated at 37ᵒC
for 1 h. Plates were washed and goat anti-mouse IgG-HRP (Southern Biotech; Birmingham,
AL) diluted 1:5,000 in 1% PBSTM was added, followed by incubation at 37ᵒC for 1 h. Plates
were washed a final time and developed with 3,3',5,5'-tetramethylbenzidine substrate (TMB).
The reaction was stopped with 2 N sulfuric acid and the absorbance at 450 nm was
immediately measured with a BioTek plate reader.
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Table 1.
Determination of optimal buffer excipient for EPT powder production.
Buffer

% Monomer
4.9
4.5
3.1
9.1
6.4

% Moisture
2.9
10.3
0
7.5
4.1

% Solubility
106
94
97
99
87

30 mM Phosphate, pH 7
30 mM Phosphate, 20 mM Mannitol, pH 7
30 mM Phosphate, 100 mM Mannitol, pH 7
30 mM Phosphate, 150 mM Mannitol, pH 7
30 mM Phosphate, 250 mM Mannitol, pH 7

3.2
1.1
5.8
5.8
6.7

31.5
14.7
2.3
3.9
5.4

67
81
97
96
91

30 mM Phosphate, pH 7.5
30 mM Phosphate, 20 mM Mannitol, pH 7.5
30 mM Phosphate, 100 mM Mannitol, pH 7.5
30 mM Phosphate, 150 mM Mannitol, pH 7.5
30 mM Phosphate, 250 mM Mannitol, pH 7.5
88 mM Phosphate, 20 mM Mannitol, pH 7

6.1
2.4
5.2
7.0
7.3
2.1

20
21.3
1
2.1
3.1
18.4

79
82
88
92
64
96

<5%

<10%

100+-10

PBS
PBS, 20 mM Mannitol
PBS, 100 mM Mannitol
PBS, 150 mM Mannitol
PBS, 250 mM Mannitol

TARGET

EPT capsule package and preparation. Torpac size M gelatin capsules were packed with
3 mg dried EPT product per capsule (corresponding to 5 µg of EPT) using the ProFunnel
capsule filling system (Torpac; Fairfield, NJ). Capsule cap and body joints were painted with
4% Eudragit L100 anionic polymer coating solution and allowed to dry for 20 min. Capsules
were loaded into a size M capsule holder and dipped just past the cap and body joints into
4% Eudragit L100 coating solution and allowed to dry for 25 min. Capsules were flipped and
reloaded into the holder and dipped past the cap and body joints into 4% Eudragit L100
coating solution. Dipping of capsules was repeated with 20% Eudragit L100 coating solution.

Capsule disintegration test. Individual EPT-containing enteric-coated capsules (n=5) were
submerged in 1 N hydrochloric acid for 2 h at room temperature. Acid submerging each
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capsule was removed and stored separately. Capsules were washed briefly with sodium
phosphate buffer (pH 6.0) followed by submersion in sodium phosphate buffer (pH 6.8).
Aliquots were removed from each tube following light vortexing at 5, 10, 15, 30, 60, 90, 120,
and 180 min and stored individually. EPT release from individual capsules was analyzed by
CTB sandwich ELISA.

CTB sandwich ELISA. The concentration of EPT standard was measured by Nanodrop
(Thermo Fisher Scientific). Plates were coated with 100 µL per well of 2.5 µg/mL of the rat
anti-CTB monoclonal antibody 7A12B3 diluted in PBS. After overnight incubation (16 to
24 h) at 4ᵒC, plates were washed three times with PBST (0.05% Tween 20 in 1X PBS) and
blocked with a blocking solution (3% bovine serum albumin, 0.05% Tween 20 in 1X PBS)
for 2 h at room temperature, then washed with PBST in triplicate. Three-fold serially diluted,
duplicate standard samples (100 µL/well) were added to plates in dilution buffer (1% bovine
serum albumin, 0.05% Tween 20 in 1X PBS). Unknown samples were diluted 1:10 in
dilution buffer and added to plates in duplicate (100 µL/well). Samples were incubated on
plates for 1 h at room temperature. Plates were washed and rabbit anti-CTB polyclonal
antibody (Abcam; Cambridge, United Kingdom) diluted 1:20,000 in dilution buffer (100
µL/well) was added; plates were then incubated at room temperature for 1 h. Plates were
washed and goat anti-rabbit IgG-HRP (Southern Biotech; Birmingham, AL) diluted
1:100,000 in dilution buffer was added, followed by incubation at room temperature for 1 h.
Plates were washed a final time and developed with TMB. The reaction was stopped with 2
N sulfuric acid and the absorbance at 450 nm was immediately measured with a BioTek plate
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reader. Percent release was determined by extrapolation of calculated EPT concentrations
using CTB sandwich ELISA compared to a known fixed mass of 5 µg EPT per capsule.

Acute DSS colitis model and EPT treatment for capsule administration study. Groups
of 10 female C57BL/6 mice, randomly assigned, were used. 3% DSS (M.W. 36,000 –
50,000; M.P. Biomedicals, Santa Ana, CA) was administered in drinking water ad libitum
for 7 days. Body weights were monitored daily from the start of DSS exposure to sacrifice
on day 14. On the last day of DSS exposure, animals were orally gavaged 100 µL PBS, 100
µL of EPT powder dissolved in PBS (0.03 mg/mL solution) after administration of sodium
bicarbonate (200µL of 30 mg/mL solution) as described previously, or enteric coated
capsules filled with 3 µg EPT (described above) [14]. Animals recovered with normal
drinking water for 7 days. Disease activity index (DAI) scores, consisting of body weight
loss, fecal consistency and occult blood tests, were recorded following sacrifice and
performed as previously described [51]. Distal colon tissues were fixed in neutral buffered
formalin and stained with hematoxalin and eosin (H&E). Histopathological scores, a
combination score comprised of crypt architecture, inflammatory infiltrate, muscle
thickening and goblet cell presences scores, were determined as previously described [52,
53]. Each category was ranked on a scale from 0 to 3 and summed to obtain a single
histopathological damage score for each tissue.

Statistics. For all data, outliers were determined by statistical analysis using the Grubb’s test
and excluded from further analysis if P < 0.05. Graphs were prepared and analyzed using
Graphpad Prism version 5.0 (Graphpad Software, La Jolla, CA). To compare two data sets,
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an unpaired, two-tailed Student’s t test was used. To compare three or more data sets, oneway ANOVA with Bonferroni’s multiple-comparison post-test was used.
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CHAPTER III: RESULTS
3.1. EPT at an intracolonic dose of 0.1 μM is most effective at mitigating acute
DSS-induced colitis.

To evaluate the efficacy of EPT and determine an optimal target dose for clinical
studies, a dose level analysis was performed using an acute DSS colitis mouse model.
Female C57Bl/6 mice (8 weeks old) were exposed to 3% DSS ad libitum in drinking
water for 7 days. Immediately upon DSS cessation mice were intracolonically
administered 100 μL PBS, 0.01 μM EPT, 0.1 μM EPT, or 1 μM EPT (corresponding to
0.0614 μg, 0.614 μg, or 6.14 μg per animal). All animals were monitored an additional 5
days following dosing. Among the three dose levels tested, 0.1 μM EPT was the only
dose that decreased disease activity index (DAI) scores in a statistically significant
manner (Figure 1A). Although not statistically significant, treatment with 1 μM and 0.01
μM EPT slightly decreased DAI scores. Histopathological assessment was performed to
corroborate the aforementioned DAI results. Similar to the DAI results, histopathological
damage scores indicate that 0.1 μM EPT was the most effective dose to mitigate DSSinduced acute colitis (Figure 1B). Interestingly, 0.01 μM EPT treatment was also
sufficient to ameliorate histological damage compared to PBS-treated mice. Treatment
with 1 μM EPT trended to a decreased histological damage score than the PBS group,
however, these results were not statistically significant.
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Figure 1. Dose level analysis of intracolonic administration of EPT. Treatment with
0.1 μM EPT is most effective at mitigating DAI and histopathological damage
scores in acute DSS colitis. (A) DAI scores of each treatment group in the DSS
acute colitis study. DAI is an average score consisting of body weight, stool
consistency, and blood in stool at time of sacrifice. (B) Histopathological damage
scores of each treatment group in the DSS acute colitis study. Histopathological
damage score is a cumulative score consisting of crypt architecture, inflammatory
infiltrates, muscle thickening, and goblet cell depletion from H&E-stained crosssections of distal colon tissue. Mean ± SD is displayed. *P < 0.05, one-way
ANOVA with Bonferroni’s multiple comparisons test.

Administration of 0.1 μM EPT most effectively protected mice from histological
damage in the distal colon compared to 0.01 or 1 μM EPT (Figure 2). Treatment with 0.1
μM EPT decreased the prevalence and incidence of crypt loss and structural alterations,
immune cell infiltrates, and goblet cell depletion compared to 0.01 μM EPT, 1 μM EPT,
and PBS groups. Dosing with 0.01 μM EPT protected from goblet cell depletion and
immune cell infiltrates, however, crypt loss and structural alterations were more common
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Figure 2. Effects of intracolonic treatment with EPT on mice colon histological
alterations induced by DSS. Mice in the 0.1 μM dose group were more protected from
crypt loss, inflammatory cell infiltration, and goblet cell depletion than any other group.
Representative 5x (left) and 20x (right) photomicrographs of H&E-stained distal colon
tissues from each treatment group.
in these tissues than the 0.1 μM EPT group. Treatment with 1 μM EPT decreased
incidences of crypt loss, immune cell infiltrates and goblet cell depletion compared to
control, but these effects were much less pronounced than in the 0.01 and 0.1 μM EPT
dosing groups.
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3.2. Pre-formulation analysis of a prototype oral formulation of EPT.

Buffers and excipients were screened to determine a combination producing
optimal EPT powder. This was determined by assessing pentamer disassembly into
monomer, residual moisture, yield, and solubility of powder in water, with a target
product profile (TPP) of < 5% monomer, < 10% moisture, and 100 ± 10 % solubility
(Table 1). Of the buffers tested, PBS and PBS + 100 mM mannitol were chosen from the
screened buffers based on the TPP values set for the aforementioned parameters. To
assess stability of the chosen buffers, pentamer degradation and water-solubility of EPT
formulated in PBS or PBS + 100 mM mannitol were analyzed over a period of three
weeks (Table 2). The screened and finalized drying conditions are summarized in Table
3. Given the importance of pentamer stability to the epithelial repair activity of EPT [30],
Table 2.
Stability of EPT powder in chosen buffer excipients.
Buffer

% Monomer

% Solubility

PBS

4.9

106

PBS, 100 mM Mannitol

3.1

97

1 Week
PBS

5.9

110

PBS, 100 mM Mannitol

4.0

97

2 Weeks
PBS

4.8

110

PBS, 100 mM Mannitol

3.3

99

3 Weeks
PBS

5.9

110

PBS, 100 mM Mannitol

3.4

99
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PBS + 100 mM mannitol was used to optimize drying conditions and subsequent
experiments. A variety of inlet and outlet temperature range combinations were assessed
to determine which would result in optimal pentamer stability. A lower inlet temperature
range (116-122 °C) and higher outlet temperature range (64-67 °C) were found to result
in the lowest degree of pentamer degradation. Therefore, these conditions were utilized
for subsequent batch productions.
Table 3
Optimization of spray-dry parameters.

Buffer
PBS
PBS
PBS
PBS
PBS, 100 mM
Mannitol
PBS, 100 mM
Mannitol
PBS, 100 mM
Mannitol*
PBS, 100 mM
Mannitol @
5mg/mL*

%
Monomer

%
Moisture

%
Solubility

Qflow
(min)

Inlet
(°C)

12.3

9.7

97

-

121

8.0

3.7

99

-

120

4.9

2.9

106

35

11

-

99

34

3.1

0

97

35

9

-

119

34

1.0

9.5

97

35

1.1

4.9

96

35

Outlet
(°C)

118125
121123
120123
121124
116122

6667
6164
6165
6163
6264
6366
6467

118122

6163

Aspirator
(%)

Pump
(%)

90

20

90

20

90

20

90

20

90

20

90

20

90

20

90

20

*Finalized drying conditions

3.3 Stability and disintegration testing of EPT capsules.

To demonstrate the stability of the chosen prototype EPT powder immediately
after spray-drying we performed a GM1/KDEL-ELISA and SEC-HPLC to detect the
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presence of intact KDEL sequence and the conformational state of CTB pentamer, which
are crucial for the mucosal healing activity of EPT [11, 30]. This immunoassay and
analytical analysis were repeated at 9 months post-spray dry with EPT powder stored
under desiccation at 23°C in parafilm-wrapped tubes. GM1/KDEL-ELISA results
demonstrate that GM1 binding affinity of spray dried EPT was unchanged after drying
(Figure 3A) and 9 months post-drying when stored under desiccation at 23°C (Figure
3B). SEC-HPLC chromatograms illustrate the stability of EPT pentamers in 9 months
post-drying (Figure 3). The small peak of 8.2% at a retention time of ~18.5 min
correlates to EPT monomers (see Figure S1), indicating only slight pentamer
degradation after 9 months post-drying stored under desiccation at 23°C (Figure3D).

Figure 3. Stability assessment of spray dried EPT. The production of EPT standard is
described in the methods section. The stability of dried EPT post-drying and after 9
months was assessed by GM1-capture KDEL-detection ELISA and SEC-HPLC. A
representative binding curve of spray dried EPT is shown for (A) one day post-drying and
(B) after 9 months stored at 23°C in a desiccator, compared to an EPT standard. SECHPLC chromatogram of (C) non-dried EPT (blue) and EPT one day post-drying (green)
and (D) dried EPT (green) after 9 months stored at 23°C in a desiccator (EPT standard is
in blue). After 9 months dried EPT contained 91.8% pentamer and 8.2% monomer
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Following packing of EPT powder into gelatin capsules and coating with an
enteric coating solution, pH-dependent release of EPT was assessed by a capsule
disintegration assay. Capsules were coated with Eudragit S100 coating solution to
prevent the release of EPT prior to arrival at the proximal colon where the intraluminal
pH has increased to ~pH6.8 after transiting through the stomach and small intestine [54,
55]. The capsule disintegration assay simulated passage of the capsule through gastric
acid and allowed us to analyze the release profile of EPT following exposure to pH 6.8.
Recovery of EPT from capsules was determined by a CTB detection sandwich
ELISA, which has the capacity to detect both GM1-binding pentamer and disassembled
CTB molecular species unlike GM1-capture ELISA (Figure 4), as EPT dissociation

Figure 4. Methodology to detect pentamer versus monomer EPT. Top left: GM1-CTB ELISA.
STD EPT in pentamer has a much higher EC50 to GM1 than acid exposed EPT which contains
EPT in monomer form. Top right: CTB sandwich ELISA. STD EPT in pentamer form and
acid exposed EPT monomer form can be detected in a similar manner demonstrating capacity
to detect both GM1-binding pentamer and disassembled CTB molecular species. Bottom: Size
Exclusion (SEC)-HPLC. STD EPT elutes in pentamer form at a 17.1-minute retention time
whereas acid exposed EPT elutes in monomer form at 19.3 minutes, whereby demonstrating
acid dissociates pentamer EPT into monomer EPT.
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could occur if the capsule content was prematurely discharged and exposed to low pH
conditions (Figure 4). The data revealed that EPT was released from the polymer-coated
capsules in a pH-dependent manner (Figure 5). No EPT was detectable at pH 1.0,
suggesting that the enteric coating prevented the release of EPT from capsules prior to
expected release at pH 6.8. The same coating solution and method was used to prepare
capsules used in the following acute colitis model.

3.4. Efficacy of EPT enteric-coated capsules in an acute colitis model.
The efficacy of EPT delivered by this oral capsule formulation was assessed compared to
standard EPT in an acute DSS colitis mouse model [14, 30]. In this model, animals were
exposed to 3% DSS ad libitum in drinking water for 7 days at which time mice were

Figure 5. EPT released from enteric-coated capsules is pH-dependent. Release of EPT
was measured by CTB sandwich ELISA. EPT releases from capsules only after
submersion at pH 6.8. Percent of EPT release from capsules after 2 h submersion in
0.1 N HCl, and at t=5, 10, 15, 30, 60, 90, 120, and 180 min after pH shift to 6.8. N=5.
Percent release was determined by extrapolation of calculated EPT concentrations
using CTB sandwich ELISA compared to a known fixed mass of 5 µg EPT per
capsule.
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Figure 6. Enteric-coated EPT capsules mitigate acute DSS colitis in mice. (A)
Study design. (B) Mice were dosed with an EPT capsule (N=10), pre-dissolved
EPT powder following gastric acid neutralization (EPT powder solution; N=9), or
capsule vehicle control (N=10) on day 7 following DSS exposure. DAI scores were
determined on day 14 as a combined measure of body weight recovery, stool
consistency, and blood in stool; data are shown as mean ± SEM. *P < 0.05, ***P <
0.001, one-way ANOVA with Bonferroni’s multiple comparisons test.

dosed 5 µg resuspended dried EPT (EPT powder solution) or PBS via oral gavage after
administration of sodium bicarbonate. A third group of mice were dosed with an entericcoated capsule containing 5 µg EPT with no administration of sodium bicarbonate. All
animals were monitored an additional 7 days following DSS cessation. Compared to
PBS, DAI scores were decreased in mice administered a EPT capsule directly as well as
sodium bicarbonate followed by reconstituted EPT powder (Figure 6). To corroborate
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Figure 7. Treatment with encapsulated EPT mitigates acute colitis in mice.
Encapsulated EPT (DSS + Capsule) treatment protected mice from histological
damage similarly to treatment with EPT powder solution following gastric acid
neutralization (DSS + EPT powder solution). (A) Representative 4x (left) and 20x
(right) photomicrographs of H&E-stained distal colon tissues from each treatment
group. (B) Histological damage scores of each treatment group in the DSS acute
colitis study. *P < 0.05, **P < 0.01; one-way ANOVA with Bonferroni’s multiple
comparisons test.
the aforementioned results, we performed a histopathological evaluation to assess the
presence of hallmark colitis markers, such as alterations in crypt height and loss,
epithelial barrier disruption, and immune cell infiltration, in hematoxalin and eosin
(H&E) stained tissues. EPT powder solution administration following gastric acid
neutralization and encapsulated EPT similarly protected mice from DSS-induced acute
colitis. Treatment with EPT by capsule administration or oral gavage following gastric
acid neutralization protected mice from crypt loss and distortion, inflammatory cell
infiltrates, muscle thickening, and goblet cell loss (Figure 7A, B). However, few crypt
structural alterations, primarily crypt branching, were noted in tissues from both EPT
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treatment groups. Taken together, these results support equivalence between EPT
treatment in solution following acid neutralization and encapsulated EPT treatment.
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CHAPTER IV: DISUSSION
EPT is a recombinant variant of the nontoxic component of the cholera toxin that
exhibits unique mucosal healing activity in the colon [14, 30, 56]. Previous studies
examining the therapeutic potential of EPT in mouse colitis models have primarily
focused on one route of administration: oral gavage. An issue with this route of
administration, however, is the need to neutralize gastric acid with sodium bicarbonate
prior to gavage as CTB is acid labile. This is a drawback when moving forward with
development of EPT as a therapeutic for UC and determining a final drug product
formulation. Although oral agents are typically preferred by patients undergoing
treatment for chronic diseases such as UC, gastric acid neutralization requirements could
potentially affect patient outcomes by lowering adherence and ease of administration.
Alternatively, we have shown that EPT also has mucosal healing activity when
administered intracolonically. Although not necessarily the ideal formulation for a
chronic disease, enemas are quite commonly used for the treatment of UC. Further, the
development of an oral formulation for an acid labile protein like EPT could slow down
efforts to begin first-in-human safety trials as more investigation and optimization is
needed to achieve production on an industrial scale. To this end, we aimed to establish an
intracolonic target dose for first-in-human trials as well as develop a prototype solid oral
formulation for that would allow EPT to circumvent gastric acid degradation and allow
for topical administration to affected areas. We described herein an encapsulated spraydried drug substance coated with an enteric coating to allow for pH-dependent release of
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EPT at the colon. This oral formulation will undergo continued development and
optimization while we move forward with a topical formulation.
The dose level analysis study described here allowed our group to identify a target
intracolonic dose of EPT. Establishing a target intracolonic dose of EPT is crucial to
justify the study design of a Phase I trial. Previous studies assessing mucosal healing by
topical delivery of EPT were primarily focused on a concentration of 1 µM, however, a
small study hinted at the efficacy of 0.1 µM (data not shown). Therefore, we elected to
compare the effects of 0.01, 0.1 and 1 µM (corresponding to 0.0614, 0.614, and 6.14
µg/animal, respectively) in an acute DSS colitis model. The DAI and histological results
indicate that 0.1 µM is the ideal target intracolonic dose of those tested. Although all
doses of EPT led to a trending decrease in DAI scores, this difference was only
significant in the 0.1 µM treatment group (Figure 1A). Similarly, treatment with 0.01 or
0.1 µM EPT, but not 1 µM, significantly decreased histopathological scores (Figure 1B).
It is currently unknown as to why EPT does not seem to induce mucosal healing in a
dose-dependent manner, however, a possibility could lie in the ability of EPT to induce
an unfolded protein response (UPR).
The UPR is activated in response to ER stress to ensure protein folding fidelity
and maintain ER functions [57]. There are three main signaling pathways of the UPR
initiated by ER transmembrane protein sensors: IRE1α, PERK, and ATF6α. The UPR is
commonly cited as a means for apoptosis of cells under chronic stress; however, recent
literature has described the necessity of the UPR to intestinal homeostasis and epithelial
barrier function [34, 35, 58, 59]. We previously demonstrated that a UPR is crucial in the
induction of mucosal healing following treatment with EPT [30]. One possible
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explanation for the decrease in efficacy with 1 µM EPT treatment is an overwhelming of
the UPR leading to apoptosis. Oral gavage of 3 µg EPT alleviates DSS colitis in mice,
which is believed to be facilitated by an EPT-induced UPR. However, a 1 µM dose of
EPT corresponds to 6.14 µg: this is more than twice the oral gavage dose. Since the UPR
often results in cell death upon overwhelming ER stress, it would be plausible that too
high of a dose of EPT could trigger this pathway rather than inducing just enough of a
response to maintain homeostasis. A limitation of this theory is the fact that a treatment
with 1 µM EPT still slightly decreased DAI and histopathological damage scores. If this
concentration of EPT were causing UPR-induced cell death, it would be thought that
disease severity would be constant, or even exacerbated, compared to PBS-treated mice.
Future studies assessing the extent of UPR upregulation following treatment with 0.01,
0.1, and 1 µM EPT could shed some light on this interesting phenomenon.
The most important insight gained from this dose-analysis study was the
identification of 0.1 µM as the target intracolonic dose of EPT. Establishing a target dose
is critical in designing future toxicology assessments and in the development of an
Investigational New Drug (IND) application. While continuing to move forward with a
topical formulation of EPT, we sought to begin investigation into potential oral
formulations for future drug product development.
A major technical advance made in the present study towards a solid oral
formulation is the establishment of the method of drying the drug substance. Drying of
pharmaceuticals is a long-implemented practice commonly used to enhance final drug
product for a variety of purposes; examples of the benefits of biopharmaceutical
dehydration include handling and storage improvement, decrease in transportation cost,
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improved stability and aid in development of modified or delayed release particles [47,
50]. It is known that proteins are more stable in solid rather than liquid form [60-63]. Use
of solid formulations can greatly increase shelf-life and reduce storage regulations, saving
patients and manufacturers money in lost production costs due to expired product.
Further, oral capsules filled with dried protein may be coated with a time- or pHdependent coating to allow for targeted release in the GI tract [47]. This is especially
useful when administering CTB orally as it allows for release at the affected site. Without
this coating, orally administered pentameric CTB would degrade into nonfunctional
monomers upon exposure to the stomach acid. Dehydrating CTB is one solution to this
issue.
Previously, CTB has been dehydrated by a variety of methods. A freeze-dried
inactivated whole-cell oral cholera vaccine was formulated in attempts to optimize
delivery of mass quantities of vaccine to low-income countries [7]. This formulation
elicited strong serum and gut mucosal anti-LPS antibody responses in immunized mice;
these responses were comparable to those achieved with equivalent liquid formulation
[7]. The dry formulation is beneficial in substantially reducing package volumes and
weights when delivering product to areas in need of mass vaccination. Further, CTB has
been successfully spray-dried in the form of heat-killed Vibrio cholerae-containing
microparticles [64]. We utilized the benefits of the spray-drying process with EPT to
develop a more optimal oral formulation of the protein. When a protein is spray-dried,
conditions need to be tailored to the protein being dried since materials undergo some
thermal stress which can result in protein degradation; hence, identification of ideal
heating conditions is critical. CTB pentamer degradation occurs approximately between
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66 and 78°C [3, 65, 66]. Therefore, we screened outlet temperature ranges between 61
and 67°C to maintain stability of functional EPT pentamer. Since we achieved optimal
TPP parameters with outlet temperatures closer to 67°C, testing outlet temperatures
closer to 78°C could possibly result in a further improved powder by solubility or
moisture content. The most relevant source of stress during spray-drying results from the
dehydration process, therefore the addition of excipients to the liquid solution prior to
spray drying is crucial to replace the hydrogen bonding that exists in an aqueous
environment [47]. In this study, a screen was developed to identify optimal excipient
conditions to improve target profile parameters.
A buffer and excipient screen to produce an ideal dried EPT powder based on a
set TPP (< 5% monomer, < 10% moisture, and 100 ± 10 % solubility). Addition of a
common excipient (mannitol) decreased the presence of EPT monomer from
approximately 5% to 3% (Table 2, 3). It is unsurprising that addition of mannitol
improved stability of EPT pentamer, as it is often used in dried pharmaceuticals due to its
thermostability [67-69]. PBS + 100 mM mannitol outperformed all other screened buffers
in the aforementioned TPP categories and was therefore chosen as the formulation buffer.
All TPP categories were met, however, loss of drug product was a consistent problem as
70% was the maximum recovery among all buffers tested (data not shown). Other studies
using this particular spray drier consistently report yields below 50% [70]. Although one
issue with this instrument is in aspects of the design, another manageable issue is
identifying an ideal inlet to outlet temperature ratio for the protein of interest [70]. This
limitation allows room for improvement moving forward in formulation development.
Stability of EPT powder produced in the chosen buffer was confirmed by measuring
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monomer content and percent solubility each week for a total of three weeks (Table 2, 3).
Low hygroscopicity of mannitol likely had a positive impact on moisture content; it is
known that mannitol is an ideal excipient to minimize moisture in a dried formulation
[68, 69]. Monomer content and solubility remained stable around 3% and 98%,
respectively, over the course of three weeks. Mannitol seems to have a protective effect
on EPT pentamers, possibly due its thermostability. This study, however, lacked
investigation of lactose as a potential excipient. Lactose is the most commonly utilized
excipient in spray drying [67, 71]. Mannitol and lactose are both attractive excipients as
they are soluble in water and are non-toxic. Lactose has an advantage to mannitol as it is
more economical, although it should be noted that lactose has a higher hygroscopicity
which can hinder stability of the dried product [67, 69]. Further, lactose is more likely to
react with active pharmaceutical ingredients as it is a reducing sugar, whereas mannitol
exhibits a strong inertness [67].
Upon selection of buffer composition, spray dry parameters were further
investigated. Spray dry parameters were optimized by screening a combination of inlet
and outlet temperatures to determine a combination producing EPT powder with the best
possible TPP values (Table 3). It has been suggested that a high inlet temperature to
outlet temperature ratio might be the key to maximizing yield . Our results are consistent
with this claim as the highest inlet:outlet temperature condition tested achieved optimal
TPP values (Table 3). We also demonstrated via SEC-HPLC and GM1-KDEL detection
ELISA that spray dried EPT maintains GM1 binding affinity and remains stable under
dry conditions for up to 9 months (Figure 4). This combination of factors indicates that
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EPT powder encapsulated immediately post-dry and after 9 months should exhibit similar
effects upon administration.
The oral formulation presented here was designed for direct delivery of EPT to
the target site by utilizing an anionic polymer coating that makes pH-dependent release at
the colon possible. The in vitro disintegration test suggested that not all capsules released
100% of encased EPT (Figure 5). It is possible that there are inconsistencies in the
thickness of the enteric coating around the capsules, leading to variations in release
profiles. The combination of dipping capsules by and viscosity of the solution could lead
to disparities between capsule coatings. This could be ameliorated by coating the
capsules using an automated system that would likely be utilized when coating capsules
at an industrial scale. Further, it was observed during disintegration testing that capsules
tend to fold in on themselves when free-floating in solution. This is an unlikely issue in
vivo as movement through the GI tract would prevent the folding over of capsules. In
support of this hypothesis, the acute DSS study showed that the enteric-coated EPT
capsule ameliorated acute DSS-induced colitis, indicating that the protein was
successfully released from the capsules at the site of mucosal damage (Figure 6, 7). The
histopathological results described here are also consistent with previous findings in
acute and chronic DSS colitis studies evaluating EPT treatment [14, 30, 36]. Taken
together, these results support further development of the capsule formulation described
herein as this treatment does not require gastric acid neutralization, which would
theoretically ease difficulty of administration and boost patient adherence in UC patients.
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CHAPTER V: CONCLUSIONS
The present studies support an established target dose of 0.1 µM for topical
administration and continued development of a capsule formulation of EPT. More
investigation is needed to uncover the lack of a dose-dependent response following EPT
treatment, as this missing piece could be vital to fully elucidating its mechanism of
action. The prototype oral formulation described here was effective at alleviating DSSinduced acute colitis but requires further optimization, primarily of the capsule coating
technique. Taken together, these results support continued development of EPT as a
therapeutic agent of UC.
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